SCHEDULE: DSS Inc. Stakeholder Adjusts Holdings

Heng Fai Ambrose Chan and associated entities have significantly reduced their beneficial ownership in DSS Inc. through share sales.

Summary

• Heng Fai Ambrose Chan, along with Alset Inc., Global Biomedical Pte. Ltd., and Alset International Limited, have filed an amendment to their Schedule 13D.
• The filing details a reduction in beneficial ownership for Heng Fai Ambrose Chan, who now holds 26,311,715 shares, representing 86.3% of the class.
• Alset Inc. beneficially owns 24,407,472 shares (80.0%), Global Biomedical Pte. Ltd. holds 311,634 shares (3.1%), and Alset International Limited holds 21,244,809 shares (71.0%).
• On September 3, 2026, Heng Fai Ambrose Chan sold 21,852 shares of DSS Inc. common stock at $0.82 per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant reduction in beneficial ownership and the sale of shares, indicating a potential decrease in confidence or strategic shift by the reporting person.

Negatives

• Heng Fai Ambrose Chan sold 21,852 shares of DSS Inc. common stock on September 3, 2026, at $0.82 per share.

Future Outlook

No specific forward-looking statements or guidance were provided in this amendment.

Industry Context

StockSavvy.ai notes that Schedule 13D filings typically report significant changes in beneficial ownership. This amendment indicates a reduction in holdings by a major stakeholder, which could signal a shift in strategy or confidence.

Stakeholder Impact

• Shareholders may view the sale of shares by a significant stakeholder as a negative signal, potentially impacting stock price.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership by a key stakeholder through a share sale. While this is a negative signal, the remaining substantial holdings suggest a 'hold' position is prudent until further strategic clarity emerges.

Keywords

Schedule 13D, Beneficial Ownership, Shareholder, Stock Sale, DSS Inc.